Home MarketSyngene International Ltd.

Syngene International Ltd. Stock Info: As on 2017-12-11 15:57:26

Nse

537.45

-3.50(-0.65%)
Change%
52 Week Range
430.10
11.00
655.00
12.00
Open539.90
Day's Range432.76 - 649.14
Value Traded (in ₹ Cr.) 3.02

Bse

536.10

-5.30(-0.98%)
Change %
52 Week Range
430.00
11.00
654.90
12.00
Open540.00
Day's Range433.12 - 649.68
Value Traded (in ₹ Cr.) 0.64

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 149,005,789.00 74.50%
Mutual Funds/UTI 2,874,400.00 1.44%
FII 31,817,463.00 15.91%
Employee 0.00 0.00%
Public 8,779,168.00 4.39%
Government 0.00 0.00%
Others 2,945,639.00 1.47%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 6.91
Basic EPS (Rs.) 11.40
Cash EPS 15.99
BVPerShare Excl 52.85
Operating Revenue 55.57
PBDITPerShare 18.27
Dividend 1.00
NPPerShare 11.10
Current Ratio 2.52
Quick Ratio 2.45
PriceToBV 7.27
Earnings 0.02
PBDIT Margin 32.87
PBT Margin 23.32
NP Margin 19.98
Return On Assets 9.25
Retention Ratios 90.95
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 1,113.10
Total Expenses 854.90
EBITDA 363.90
PBT 258.20
PAT 221.20
Net Income 221.20
More
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 614.90
Total Expenses 466.10
EBITDA 97.50
PBT 146.60
PAT 125.30
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 199.20
Net worth 1,052.80
Investments 276.40
Total Liability 2,389.50
Total debt 891.00
Net block 817.00
Total Assets 2,389.50
Parameter Mar-16 (₹ Cr.) 6M % change
Total share capital 199.20
Net worth 1,052.80
Investments 276.40
Total Liability 2,389.50
Total debt 891.00
Net block 817.00
Total Assets 2,389.50
Company Curr Price Prev. Close Change% W's Low/High

Adani Ports & Special Economic Zone Ltd.

391.75 393.4 -0.42
377.35396.9

Banaras Beads Ltd.

63.45 63.55 -0.16
6266

Binani Industries Ltd.

96.85 98.05 -1.22
90103.75

Career Point Ltd.

133.2 133.5 -0.22
128.9141.5

Dredging Corporation Of India Ltd.

657.2 646.95 1.58
623.05663.3

Future Consumer Ltd.

67 68.05 -1.54
56.969.15

Gateway Distriparks Ltd.

241.6 240 0.67
237.45249.9
Company Curr Price Prev. Close Change% W's Low/High

Adani Ports & Special Economic Zone Ltd.

390.95 392.6 -0.42
378396.55

Alpha Hi-Tech Fuel Ltd.

0.87 0.91 -4.39
0.870.87

Anil Ltd.

32 30.85 3.73
29.431.85

Bagalkot Udyog Ltd.

23.9 25.15 -4.97
23.923.9

Banaras Beads Ltd.

64.1 63.4 1.1
6168.5

Binani Industries Ltd.

97 97.95 -0.97
90.3104

Brahmanand Himghar Ltd.

4.08 4.29 -4.9
4.084.08
More
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities 312.40
Cash from investing activities -748.80
Cash from financing activities 709.40
Net change in cash 271.60

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
Reliance Regular Savings Fund - Equity 1.65%
Motilal Oswal Most Focused Long Term Fund 3.35%
Canara Robeco Emerging Equities 0.64%
Motilal Oswal MOSt Focused Dynamic Equity Fund 1.25%
Axis Small Cap Fund 2.82%
Invesco India Mid N Small Cap Fund 1.55%

Kellton Tech Solutions Q2 net down 9% at Rs 2.24 cr

Kellton Tech Solutions has reported standalone net profit of Rs 2.24 crore for the quarter ended September 30, 2017 as compared to Rs 2.46 crore in the same period last year, registering a year-on-year decline of 8.94 per cent. Net revenue of the company rose substantially by 26.00 per cent at Rs 22.97 crore in July-September quarter of this fiscal as against Rs 18.23 crore in the corresponding period last year. During July-September quarter, operating expenses increased by 33.97 per cent to Rs 18.89 crore from Rs 14.10 crore in year ago period. Other Income grew by 2250.00 per cent at Rs 0.47 crore versus (Sep'16 Rs 0.02 crore). Operating Profit slipped by 1.21 per cent to Rs 4.08 crore as against Rs 4.13 crore in the year ago period, while Operating Profit Margin (OPM) contracted year-on-year to 21.47 per cent in September quarter.

11-12-2017 09:19

Thyrocare Tech Q2 net profit up 15% at Rs 23.44 cr

Thyrocare Technologies, an operator of medical labs, has reported standalone net profit of Rs 23.44 crore for the quarter ended September 30, 2017 as compared to Rs 20.40 crore in the same period last year, registering a year-on-year growth of 14.90 per cent. Net revenue of the company rose moderately by 7.86 per cent at Rs 81.79 crore in July-September quarter of this fiscal as against Rs 75.83 crore in the corresponding period last year. During July-September quarter, operating expenses dropped by 0.46 per cent to Rs 47.82 crore from Rs 48.04 crore in year ago period. Other Income dipped by 7.89 per cent at Rs 3.15 crore versus (Sep'16 Rs 3.42 crore). Operating Profit surged by 12.56 per cent to Rs 33.97 crore as against Rs 30.18 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 4.37 per cent in September quarter.

11-12-2017 09:18

Sharda Motor Q2 net jumps 71% at Rs 20.26 cr

Sharda Motor Industries has reported standalone net profit of Rs 20.26 crore for the quarter ended September 30, 2017 as compared to Rs 11.85 crore in the same period last year, registering a year-on-year growth of 70.97 per cent. Net revenue of the company rose moderately by 17.81 per cent at Rs 304.74 crore in July-September quarter of this fiscal as against Rs 258.66 crore in the corresponding period last year. During July-September quarter, operating expenses increased by 18.61 per cent to Rs 268.29 crore from Rs 226.20 crore in year ago period. Other Income grew by 43.30 per cent at Rs 5.13 crore versus (Sep'16 Rs 3.58 crore). Operating Profit surged by 7.30 per cent to Rs 36.44 crore as against Rs 33.96 crore in the year ago period, while Operating Profit Margin (OPM) contracted year-on-year to 8.91 per cent in September quarter.

11-12-2017 09:14

Airtel to connect over 2100 uncovered villages in North East

Telecom services provider Airtel said it will provide mobile connectivity in 2,100 uncovered villages and on national highways in north-eastern states in next 18 months, reported PTI. Bharti Airtel has signed an agreement with Department of Telecom (DoT) and the Universal Service Obligation Fund (USOF) for provision of mobile services in identified uncovered villages and national highways in the north-eastern states of Assam, Manipur, Mizoram, Nagaland, Sikkim, Tripura and Arunachal Pradesh, Airtel said in a statement. Under the agreement, it said that Airtel will set up over 2,000 mobile towers/sites in unconnected pockets of the region and deliver telecom connectivity to citizens in over 2,100 villages over the next 18 months. The deployment will also boost connectivity along important national highways in the region. Airtel would receive about Rs 1,610 crore from the USOF for executing the project. The telecom infrastructure set up by Airtel will also enable other telecom service providers to offer services in the region, thereby, providing a major fillip to telecom connectivity in the region, which is characterised by tough terrain.

11-12-2017 00:32

Indiabulls Housing sells 100% stake in Indiabulls Life

Indiabulls Housing Finance said it has sold its entire shareholding in Indiabulls Life Insurance Company for a cash consideration of Rs 5 lakh to SORIL Holdings and Ventures, reported PTI. The company has sold its 100 per cent shareholding in 'Indiabulls Life Insurance Company Limited', presently a non- operational company with no business or license, to SORIL Holdings and Ventures Limited ('SHVL'), at face value for an aggregate cash consideration of Rs 5 lac, Indiabulls Housing Finance Ltd said in a BSE filing. This transaction between the company and the SHVL, being related parties, is at arms' length, it added.

11-12-2017 00:27

Syngene partners Bristol-Myers Squibb for R&D operations

Syngene International, India’s largest contract research organization has said that it has expanded its ongoing collaboration with Bristol-Myers Squibb. The next phase of the partnership will see the addition of a new facility to support future Bristol-Myers Squibb research and development operations, an expansion of the team and the extension of the existing agreement through 2026. The expansion will enable the two companies to undertake a greater range of scientific research and development for pharmaceuticals across a broader range of activities. Syngene and Bristol-Myers Squibb have worked together since 1998. The research campus, known as Biocon BMS Research Center (BBRC), Syngene’s first dedicated R&D Center, was established in 2007, which was subsequently renewed through 2020 and now has been further extended through 2026. It is the largest research and development facility for Bristol-Myers Squibb outside of the United States and plays an integral part within their global research and development network. Meanwhile, shares of the company were trading at Rs 499.45 apiece, up 0.96 per cent from the previous close at 11:01 hours on BSE.

14-Nov-2017 11:01 AM

Syngene Internationa - Press Release

Syngene International Limited has informed the Exchange regarding a press release dated November 14, 2017, titled Bristol-Myers Squibb and Syngene International Expand Ongoing Research Collaboration..

14-Nov-2017 08:36 AM

Syngene Internationa - Press Release / Media Release

Bristol-Myers Squibb and Syngene International Expand Ongoing Research Collaboration.

14-Nov-2017 08:33 AM

Syngene Internationa - Analyst / Investor Meet - Intimation

Intimation of Schedule of Meetings with Analysts/Institutional Investor under regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

03-Nov-2017 02:59 PM

Syngene Internationa - Analysts/Institutional Investor Meet/Con. Call Updates

Syngene International Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates

03-Nov-2017 02:57 PM

Syngene Internationa - Press Release / Media Release

Bristol-Myers Squibb and Syngene International Expand Ongoing Research Collaboration.

14-Nov-2017 08:33 AM

Syngene Internationa - Analyst / Investor Meet - Intimation

Intimation of Schedule of Meetings with Analysts/Institutional Investor under regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

03-Nov-2017 02:59 PM

Syngene Internationa - Investor Presentation

Investor Presentation under regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

03-Nov-2017 02:47 PM

Corporate Details

About Management

The Company was incorporated as Syngene International Private Limited on November 18, 1993 at Bengaluru, Karnataka as a private limited company under the Companies Act, 1956. Pursuant to a special resolution of the shareholders dated March 26, 2007, the Company was converted into a public limited company and the name of the Company was changed to Syngene International Limited. A fresh certificate of incorporation consequent upon conversion to public limited company was issued on April 19, 2007. the Company was promoted by Kiran Mazumdar Shaw, a promoter of Biocon. On March 30, 2002, 99.9 percent of the Equity Shares of the Company were transferred to Biocon and as a result, the Company became the subsidiary of Biocon. Biocon has since been the Promoter of the Company.The details of changes in the registered office of the Company are given below: From 20th KM, Hosur Road, Electronics City P.O, Bengaluru 560 100, Karnataka, India to Biocon Special Economic Zone, Biocon Park, Plot No. 2 and 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Bengaluru 560 099, Karnataka, India. Major events and milestones of the Company : 1994 -Initiated operations as a CRO with services in chemistry and biology 1998 -Granted 100% Export Oriented Unit (EOU) status by the Government of India 1999 -First operational expansion in R&D by way of expansion of lab space to over 23,000 sq. ft. 2000 -CIL was incorporated as a 100% subsidiary of Biocon to provide clinical research services to domestic and multinational companies 2001 -Forayed into chemical development with a dedicated manufacturing facility 2003 -Moved to Biocon Park, a 90 acre biopharmaceutical SEZ with operations spread over 65,000 sq. ft. 2007 -Bristol-Myers Squibb and the Company signed the first long term contract to set up the first dedicated R&D centre -Expansion of research facilities at Biocon SEZ to 148,000 sq. ft. -Crossed an annual turnover of over `1,000 million in Financial Year 2007 2009 -Dupont Crop Protection and the Company extended a partnership for R&D services -Expansion of manufacturing services with a new plant which is cGMP compliant -Initiated operations in safety assessment and large molecules development services 2010 -Acceptance of the clinical and bio-analytical facilities of CIL by the Department of Health & Human Services, FDA -Initiated operations in formulation development 2011 -Endo Pharmaceuticals and the Company collaborated to develop novel biological therapeutic molecules against cancer 2012 -Abbott and the Company collaborated to establish Abbott's nutrition research and development centre in India and the second R&D centre -Certification of the clinical facilities by ANVISA -Acquired 100% stake in Clinigene International Limited from Biocon 2013 -Crossed an annual turnover of over `5,000 million in Financial Year 2013 -Baxter International Inc. collaborated with the Company to establish the `Baxter Global Research Center', the third dedicated R&D centre -Acceptance of the control testing laboratory by the Department of Health & Human Services, FDA 2014 -Bristol-Myers Squibb and the Company extend collaboration for its dedicated R&D centre till 2020 -Acceptance of the API manufacturing facility by the Department of Health & Human Services, FDA -Established a 75,000 sq.ft centre to provide stability and analytical services 2015 -CIL was amalgamated with the Company Awards, Recognitions and Accreditations : 2009 - Bangalore Bio, Bio Excellence Award - Biotech Services Sector - Best BioServices company of the year by Biospectrum 2012 - ISO 9001:2008 for contract research in drug discovery and contract manufacturing of biopharmaceuticals - AAALAC accreditation for conforming to the "Guide for the Care and Use of Laboratory Animals and the Committee for the Purpose of Control and Supervision of Experiments on Animals guidelines" 2013 - Bioservices - ABLE Tenth Anniversary Award - Outstanding contribution to Bioservices - Diamond sponsor recognition by the Association of Scientists of Indian Origin of the Society of Toxicology 2014 - ISO 14001:2004 for contract research in drug discovery and contract manufacturing of biopharmaceuticals - BS OHSAS 18001:2007 for contract research in drug discovery and contract manufacturing of biopharmaceuticals - Silver EDGE Award - EHS best practices award by CII - SAP Ace Award for special recognition for complex SAP implementation - Level I Laboratory certification issued by the NGSP to Clinigene International Limited 2015 - Accreditation by the College of American Pathologists in relation to their laboratory accreditation program - Bangalore India Bio - Bio Excellence Award for outstanding contribution to the Biotech services sector - ISO 15189:2007 in the field of medical testing

Registered Office

113-C - 2, Bommasandra Industrial Area, Attibele Hobli, Anekal Taluk,

,,,      ,

Registrar Details

Karvy Computershare Private Ltd.